ACCD

Leerink Partners Initiates Coverage of Accolade (ACCD) with Outperform Recommendation

Fintel reports that on February 26, 2024, Leerink Partners initiated coverage of Accolade (NasdaqGS:ACCD) with a Outperform recommendation.

Analyst Price Forecast Suggests 49.71% Upside

As of February 24, 2024, the average one-year price target for Accolade is 15.30. The forecasts range from a low of 12.12 to a high of $18.90. The average price target represents an increase of 49.71% from its latest reported closing price of 10.22.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Accolade is 414MM, an increase of 6.53%. The projected annual non-GAAP EPS is -2.04.

What is the Fund Sentiment?

There are 330 funds or institutions reporting positions in Accolade. This is a decrease of 16 owner(s) or 4.62% in the last quarter. Average portfolio weight of all funds dedicated to ACCD is 0.08%, an increase of 15.83%. Total shares owned by institutions increased in the last three months by 10.33% to 81,030K shares. ACCD / Accolade, Inc. Put/Call Ratios The put/call ratio of ACCD is 1.66, indicating a bearish outlook.

What are Other Shareholders Doing?

ACCD / Accolade, Inc. Shares Held by Institutions

ARK Investment Management holds 6,805K shares representing 8.79% ownership of the company. In it's prior filing, the firm reported owning 6,043K shares, representing an increase of 11.21%. The firm decreased its portfolio allocation in ACCD by 1.07% over the last quarter.

Jpmorgan Chase holds 6,410K shares representing 8.28% ownership of the company. In it's prior filing, the firm reported owning 6,582K shares, representing a decrease of 2.68%. The firm decreased its portfolio allocation in ACCD by 3.72% over the last quarter.

Brown Advisory holds 5,963K shares representing 7.70% ownership of the company. In it's prior filing, the firm reported owning 6,066K shares, representing a decrease of 1.74%. The firm decreased its portfolio allocation in ACCD by 4.44% over the last quarter.

ARKG - ARK Genomic Revolution ETF holds 5,923K shares representing 7.65% ownership of the company. In it's prior filing, the firm reported owning 5,939K shares, representing a decrease of 0.28%. The firm decreased its portfolio allocation in ACCD by 24.89% over the last quarter.

AH Capital Management, L.L.C. holds 5,399K shares representing 6.97% ownership of the company.

Accolade Background Information
(This description is provided by the company.)

Accolade, Inc. of Pennsylvania provides healthcare related information for self-insured companies. The Company assists employees and their families to make healthcare decisions through its health assistants. Accolade serves customers in the United States.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.